Lakefront Biotherapeutics NV
LKFTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Lakefront Biotherapeutics NV focuses on Biotechnology services and products. Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The $2.09B market capitalization puts LKFT squarely in mid-cap range for its industry. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Market Cap
$2.09B
Beta
0.06
P/E (TTM)
3.01
P/E (Fwd)
-26.58
EPS (TTM)
$10.52
EPS (Fwd)
$-1.19
ROE
20.1%
ROA
9.9%
Cash
$2.24B
Total Debt
$6.4M
Free CF
$138.2M
52W Change
1.9%
Annual Financials
Cash vs Debt
Where LKFT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LKFT finished 3.51% above its 150-day moving average ($28.78) and 0.67% below its 200-day moving average ($29.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LKFT overbought or oversold?
At the October 20, 2026 close, LKFT's RSI(14) was 52.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Lakefront Biotherapeutics NV holds $2.24B in cash against $6.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $138.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 20.1% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 9.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $241.2M (2022) to $1.11B (2025), reflecting a 361% increase over the period.
LKFT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing LKFT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.